title: Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.
abstract: OBJECTIVE
  The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer.
  
  
  METHODS
  One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software.
  
  
  RESULTS
  Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001).
  
  
  CONCLUSIONS
  The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.
authors.affiliation: Department of Urology, Akita University School of Medicine, Akita, Japan.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Tsuchiya
authors.forename: Lizhong
authors.initials: L
authors.lastname: Wang
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Takehiko
authors.initials: T
authors.lastname: Segawa
authors.forename: Hisami
authors.initials: H
authors.lastname: Fukuda
authors.forename: Shintaro
authors.initials: S
authors.lastname: Narita
authors.forename: Masaki
authors.initials: M
authors.lastname: Shimbo
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kamoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsumori
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ichikawa
authors.forename: Osamu
authors.initials: O
authors.lastname: Ogawa
authors.forename: Akira
authors.initials: A
authors.lastname: Nakamura
authors.forename: Tomonori
authors.initials: T
authors.lastname: Habuchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001141:Aromatase / Q000235:genetics*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011110:Polymorphism, Genetic; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D012091:Repetitive Sequences, Nucleic Acid
chemical_list: D007334:Insulin-Like Growth Factor I; D001141:Aromatase